In addition, combined treatment with anti-CTLA-4 and either 5-AZA-CdR [22] or the second-generation DNMT inhibitor guadecitabine [23] significantly reduced the growth of poorly immunogenic syngeneic grafts of murine mammary carcinoma TS/A and of mesothelioma AB1 with respect to treatment with the single agents. This evidence concerns the gene CTLA4 and mesothelioma.